Literature DB >> 11979339

T-lymphocyte populations and cytokines in childhood nephrotic syndrome.

Giuliana Lama1, Ilaria Luongo, Giuseppina Tirino, Adriana Borriello, Ciro Carangio, Maria Esposito Salsano.   

Abstract

We investigated lymphocyte subpopulations and the production of cytokines by T helper cell subtype 1 (Th1), Th2, and monocytes/macrophages (tumor necrosis factor-alpha [TNF-alpha]) in peripheral-blood mononuclear cells of 18 children with steroid-sensitive (SS) nephrotic syndrome (NS) and 10 children with steroid-resistant (SR) NS. Mean age was 10.9 +/- 5.7 years, with a mean follow-up before the study of 6 +/- 5 years. To evaluate the possible relationship between cytokine levels and response to treatment, patients with SS and SR NS were assessed during relapse/marked proteinuria (group A), total/partial remission (group B), and off treatment (group C). In children with SS and SR NS, we found no significant difference in CD3 counts compared with controls. The proportion of CD4 cells decreased significantly in relapse and off therapy compared with controls in children with SS NS, whereas in those with SR NS, there was a concomitant reduction in all groups. B-Lymphocyte counts were significantly increased in either group versus controls. In SR NS, CD8 and natural killer cell levels increased during relapse versus controls. The CD4+/CD8+ ratio was reduced to the same degree in those with SS and SR NS. In patients with SR NS, we observed increased levels of soluble interleukin-2 (IL-2) receptor (sIL-2R) from corresponding control values (P < 0.01). A significant increase in TNF-alpha levels was found in patients with SS and SR NS versus controls. High levels of IL-2, sIL-2R, and interferon-gamma during relapse in patients with SS NS give further evidence for a Th1 pattern that might be involved in the pathogenesis of NS, and monitoring the Th1/Th2 balance would be useful in evaluating the response to therapy. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979339     DOI: 10.1053/ajkd.2002.32769

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  48 in total

1.  Long-term remission of nephrotic syndrome with etanercept for concomitant juvenile idiopathic arthritis.

Authors:  Shuichi Ito; Akiko Tsutsumi; Tomonori Harada; Aya Inaba; Shuichiro Fujinaga; Koichi Kamei
Journal:  Pediatr Nephrol       Date:  2010-06-09       Impact factor: 3.714

2.  Clinical features and outcome of childhood minimal change nephrotic syndrome: is genetics involved?

Authors:  Anne-Tiina Lahdenkari; Maija Suvanto; Eero Kajantie; Olli Koskimies; Marjo Kestilä; Hannu Jalanko
Journal:  Pediatr Nephrol       Date:  2005-06-21       Impact factor: 3.714

3.  T regulatory cell function in idiopathic minimal lesion nephrotic syndrome.

Authors:  Carlos Araya; Leila Diaz; Clive Wasserfall; Mark Atkinson; Wei Mu; Richard Johnson; Eduardo Garin
Journal:  Pediatr Nephrol       Date:  2009-06-03       Impact factor: 3.714

Review 4.  The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies.

Authors:  Wagner de Fátima Pereira; Gustavo Eustáquio Alvim Brito-Melo; Fábio Tadeu Lourenço Guimarães; Thiago Guimarães Rosa Carvalho; Elvis Cueva Mateo; Ana Cristina Simões e Silva
Journal:  Inflamm Res       Date:  2014-01       Impact factor: 4.575

Review 5.  Immunology of idiopathic nephrotic syndrome.

Authors:  Manuela Colucci; Giorgia Corpetti; Francesco Emma; Marina Vivarelli
Journal:  Pediatr Nephrol       Date:  2017-04-27       Impact factor: 3.714

6.  A distinct lymphocyte distribution in relapse after rituximab for steroid-dependent nephrotic syndrome.

Authors:  Masaki Shimizu; Tadafumi Yokoyama; Sayaka Ishikawa; Kazuyuki Ueno; Kazuhide Ohta; Akihiro Yachie
Journal:  CEN Case Rep       Date:  2012-08-09

7.  Characterisation of renal immune cell infiltrates in children with nephrotic syndrome.

Authors:  Kerstin Benz; Maike Büttner; Katalin Dittrich; Valentina Campean; Jörg Dötsch; Kerstin Amann
Journal:  Pediatr Nephrol       Date:  2010-04-13       Impact factor: 3.714

8.  Stem cell mobilization in idiopathic steroid-sensitive nephrotic syndrome.

Authors:  Hélène Lapillonne; Annelaure Leclerc; Tim Ulinski; Laurent Balu; Arnaud Garnier; Nathalie Dereuddre-Bosquet; Hervé Watier; Marie-Hélène Schlageter; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2008-05-06       Impact factor: 3.714

9.  Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Authors:  Kerstin Benz; Jörg Dötsch; Wolfgang Rascher; Daniel Stachel
Journal:  Pediatr Nephrol       Date:  2004-04-08       Impact factor: 3.714

10.  Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Authors:  Melanie S Joy; Debbie S Gipson; Leslie Powell; Jacqueline MacHardy; J Charles Jennette; Suzanne Vento; Cynthia Pan; Virginia Savin; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Am J Kidney Dis       Date:  2009-11-22       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.